Compugen Ltd. (CGEN)
Compugen Ltd. (CGEN) Stock Price, Analysis & Data
| Bid | 1.7 |
| Market Cap | 225.44M |
| Revenue (ttm) | 74M |
| Net Income (ttm) | 35.19M |
| Beta | 2.78 |
| EPS (ttm) | 0.38 |
| PE Ratio (ttm) | 6.26 |
| Forward PE | -6.49 |
| P/B (ttm) | 2.54 |
| P/S (ttm) | 3.05 |
| Earnings Date | Nov 9, 2026 |
| Ask | 2.95 |
| Volume | 98,026 |
| Avg. Volume (20D) | 328,320 |
| Open | 2.33 |
| Previous Close | 2.35 |
| Day's Range | 2.31 - 2.39 |
| 52-Week Range | 1.30 - 3.24 |
| Analyst | Strong Buy |
| Price Target | 4 (68.07%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of sol...
Financial Performance
In 2025, Compugen's revenue was 72.76M, an increase of 161.14% compared to the previous year's 27.86M. Earnings were 35.34M, a decrease of -348.35%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for CGEN stock is "Strong Buy". The 12-month stock price forecast is 4, which is upside of 68.07% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
